Wedbush Cuts Halozyme Therapeutic to Neutral (HALO)
Posted by Kristian Gore on Jan 30th, 2013 // No Comments
Wedbush cut shares of Halozyme Therapeutic (NASDAQ: HALO) from an outperform rating to a neutral rating in a research note issued to investors on Wednesday.
A number of other analysts have also recently weighed in on HALO. Analysts at Jefferies Group reiterated an underperform rating on shares of Halozyme Therapeutic in a research note to investors on Wednesday. They now have a $4.00 price target on the stock. Analysts at BMO Capital Markets upgraded shares of Halozyme Therapeutic from a market perform rating to an outperform rating in a research note to investors on Monday, January 14th. They now have a $12.00 price target on the stock, up previously from $4.00.
Six equities research analysts have rated the stock with a buy rating, one has assigned a hold rating, and one has issued a sell rating to the company’s stock. The company has an average rating of overweight and an average price target of $10.07.
ANILyst's, are LESS reliable than ECONOMISTS, plus so many of them have an agenda/are CROOKED!!!!! LOL :-)
"Six investment analysts have rated the stock (HALO) with a buy rating, one has given a hold rating, and one has assigned a sell rating to the company’s stock. The company presently has a consensus rating of “overweight” and a consensus target price of $10.07."